28005193|t|TREK-1 (K2P2.1) K(+) channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control
28005193|a|Atrial fibrillation (AF) is the most common cardiac arrhythmia. Concomitant heart failure (HF) poses a particular therapeutic challenge and is associated with prolonged atrial electrical refractoriness compared with non-failing hearts. We hypothesized that downregulation of atrial repolarizing TREK-1 (K2P2.1) K(+) channels contributes to electrical remodeling during AF with HF, and that TREK-1 gene transfer would provide rhythm control via normalization of atrial effective refractory periods in this AF subset. In patients with chronic AF and HF, atrial TREK-1 mRNA levels were reduced by 82% (left atrium) and 81% (right atrium) compared with sinus rhythm (SR) subjects. Human findings were recapitulated in a porcine model of atrial tachypacing-induced AF and reduced left ventricular function. TREK-1 mRNA (-66%) and protein (-61%) was suppressed in AF animals at 14-day follow-up compared with SR controls. Downregulation of repolarizing TREK-1 channels was associated with prolongation of atrial effective refractory periods versus baseline conditions, consistent with prior observations in humans with HF. In a preclinical therapeutic approach, pigs were randomized to either atrial Ad-TREK-1 gene therapy or sham treatment. Gene transfer effectively increased TREK-1 protein levels and attenuated atrial effective refractory period prolongation in the porcine AF model. Ad-TREK-1 increased the SR prevalence to 62% during follow-up in AF animals, compared to 35% in the untreated AF group. In conclusion, TREK-1 downregulation and rhythm control by Ad-TREK-1 transfer suggest mechanistic and potential therapeutic significance of TREK-1 channels in a subgroup of AF patients with HF and prolonged atrial effective refractory periods. Functional correction of ionic remodeling through TREK-1 gene therapy represents a novel paradigm to optimize and specify AF management.
28005193	0	29	TREK-1 (K2P2.1) K(+) channels	T103	UMLS:C0754471
28005193	62	81	atrial fibrillation	T038	UMLS:C0004238
28005193	86	99	heart failure	T038	UMLS:C0018801
28005193	151	170	Atrial fibrillation	T038	UMLS:C0004238
28005193	172	174	AF	T038	UMLS:C0004238
28005193	195	213	cardiac arrhythmia	T033	UMLS:C0003811
28005193	215	240	Concomitant heart failure	T038	UMLS:C0018801
28005193	242	244	HF	T038	UMLS:C0018801
28005193	277	286	challenge	T058	UMLS:C1315011
28005193	320	352	atrial electrical refractoriness	T038	UMLS:C0034954
28005193	367	385	non-failing hearts	T017	UMLS:C0018787
28005193	408	422	downregulation	T038	UMLS:C0013081
28005193	426	445	atrial repolarizing	T038	UMLS:C1371280
28005193	446	475	TREK-1 (K2P2.1) K(+) channels	T103	UMLS:C0754471
28005193	491	512	electrical remodeling	T038	UMLS:C3658220
28005193	520	522	AF	T038	UMLS:C0004238
28005193	528	530	HF	T038	UMLS:C0018801
28005193	541	561	TREK-1 gene transfer	T062	UMLS:C1517499
28005193	595	608	normalization	T062	UMLS:C1882115
28005193	612	647	atrial effective refractory periods	T033	UMLS:C0428938
28005193	656	658	AF	T038	UMLS:C0004238
28005193	659	665	subset	T062	UMLS:C2986480
28005193	684	694	chronic AF	T038	UMLS:C0694539
28005193	699	701	HF	T038	UMLS:C0018801
28005193	703	716	atrial TREK-1	T103	UMLS:C0754471
28005193	717	721	mRNA	T103	UMLS:C0035696
28005193	750	761	left atrium	T017	UMLS:C0225860
28005193	772	784	right atrium	T017	UMLS:C0225844
28005193	800	812	sinus rhythm	T033	UMLS:C0232201
28005193	814	816	SR	T033	UMLS:C0232201
28005193	818	826	subjects	T098	UMLS:C0080105
28005193	828	833	Human	T204	UMLS:C0086418
28005193	834	842	findings	T033	UMLS:C0243095
28005193	884	913	atrial tachypacing-induced AF	T038	UMLS:C0004238
28005193	926	951	left ventricular function	T038	UMLS:C0080310
28005193	953	959	TREK-1	T103	UMLS:C0754471
28005193	960	964	mRNA	T103	UMLS:C0035696
28005193	976	983	protein	T103	UMLS:C0754471
28005193	1009	1011	AF	T038	UMLS:C0004238
28005193	1012	1019	animals	T204	UMLS:C0003062
28005193	1054	1056	SR	T033	UMLS:C0232201
28005193	1067	1081	Downregulation	T038	UMLS:C0013081
28005193	1085	1097	repolarizing	T038	UMLS:C1371280
28005193	1098	1113	TREK-1 channels	T103	UMLS:C0754471
28005193	1150	1185	atrial effective refractory periods	T033	UMLS:C0428938
28005193	1236	1248	observations	T062	UMLS:C0302523
28005193	1252	1258	humans	T204	UMLS:C0086418
28005193	1264	1266	HF	T038	UMLS:C0018801
28005193	1307	1311	pigs	T204	UMLS:C0039005
28005193	1317	1327	randomized	T062	UMLS:C0034656
28005193	1338	1367	atrial Ad-TREK-1 gene therapy	T058	UMLS:C0017296
28005193	1371	1385	sham treatment	T058	UMLS:C0032042
28005193	1387	1400	Gene transfer	T062	UMLS:C1517499
28005193	1423	1437	TREK-1 protein	T103	UMLS:C0754471
28005193	1460	1494	atrial effective refractory period	T033	UMLS:C0428938
28005193	1533	1542	Ad-TREK-1	T103	UMLS:C0754471
28005193	1557	1559	SR	T033	UMLS:C0232201
28005193	1598	1600	AF	T038	UMLS:C0004238
28005193	1601	1608	animals	T204	UMLS:C0003062
28005193	1643	1645	AF	T038	UMLS:C0004238
28005193	1668	1674	TREK-1	T103	UMLS:C0754471
28005193	1675	1689	downregulation	T038	UMLS:C0013081
28005193	1712	1730	Ad-TREK-1 transfer	T062	UMLS:C1517499
28005193	1739	1776	mechanistic and potential therapeutic	T058	UMLS:C0087111
28005193	1793	1808	TREK-1 channels	T103	UMLS:C0754471
28005193	1814	1822	subgroup	T170	UMLS:C1515021
28005193	1826	1828	AF	T038	UMLS:C0004238
28005193	1843	1845	HF	T038	UMLS:C0018801
28005193	1860	1895	atrial effective refractory periods	T033	UMLS:C0428938
28005193	1947	1966	TREK-1 gene therapy	T058	UMLS:C0017296
28005193	2019	2021	AF	T038	UMLS:C0004238